Biotech

Biotech Investing

Q BioMed Inc. (OTCQB:QBIO) partner Mannin Research Inc. CSO Dr. Susan Quaggin discusses glaucoma, treatment options, and her novel findings on the relationship between Tie2/TEK signaling, Schelmm’s Canal and glaucoma with Eye on Vision.

Q BioMed Inc. (OTCQB:QBIO) partner Mannin Research Inc. CSO Dr. Susan Quaggin discusses glaucoma, treatment options, and her novel findings on the relationship between Tie2/TEK signaling, Schelmm’s Canal and glaucoma with Eye on Vision. In the interview Dr. Quaggin explains intraocular pressure (IOP), one of the major causes of glaucoma and her research into understanding Tie2/TEK signalling and its relationship with Schlemm’s Canal function and regulation of intra-ocular pressure.
Mannin’s researchers have received the first of several drug candidates for testing. Once finalized, the lead candidates will be formulated for clinical testing in a topical application in the form of an easy to administer eye drop. This is a key differentiator for Mannin and aims to solve the compliance problems and invasive procedures currently available to patients suffering from glaucoma.
In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics including the technology discussed here.
To listen to the interview, please visit the Eye On Vision podcast here.
Connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.
 

MARKETS

Markets
TSX19078.64-144.10
TSXV626.34-18.57
DOW31029.31+82.32
S&P 5003818.83-2.72
NASD11177.89-3.65
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1818.74+0.17
Silver20.74-0.08
Copper3.780.00
Palladium1961.50+92.50
Platinum919.50+9.50
Oil109.64-0.14
Heating Oil3.950.00
Natural Gas6.44-0.06

DOWNLOAD FREE REPORTS

×